Menu
Search
|

Menu

Close
X

Solid Biosciences Inc SLDB.OQ (NASDAQ Stock Exchange Global Select Market)

43.11 USD
-1.00 (-2.27%)
As of Jul 21
chart
Previous Close 44.11
Open 44.11
Volume 53,322
3m Avg Volume 108,428
Today’s High 44.13
Today’s Low 41.50
52 Week High 54.51
52 Week Low 6.83
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.448
FY17
-1.220
FY16
-0.195
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Andrey Zarur
Chairman of the Board, Co-Founder, Since
Salary: --
Bonus: --
Martin Freed
President, Director, Since 2018
Salary: --
Bonus: --
Ilan Ganot
Chief Executive Officer, Co-Founder, Director, Since
Salary: --
Bonus: --
Alvaro Amorrortu
Chief Operating Officer, Since
Salary: --
Bonus: --
Jorge Quiroz
Chief Medical Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

141 Portland St Fl 5
CAMBRIDGE   MA   02139-1937

Phone: +1617.3374682

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

SPONSORED STORIES